期刊文献+

宁波市2004-2015年抗病毒治疗HIV/AIDS患者生存分析 被引量:18

Survival analysis of HIV/AIDS patients with access to highly antiretroviral therapy in Ningbo during 2004-2015
原文传递
导出
摘要 目的 了解2004-2015年宁波市接受抗病毒治疗的HIV/AIDS患者流行病学特征及生存情况。方法 采用回顾性队列研究方法,对研究对象的流行病学特征进行描述性分析,利用寿命表法计算生存率、Kaplan-Meier法绘制生存曲线、Cox比例风险回归模型分析影响死亡的危险因素。结果 2 347例研究对象中,接受抗病毒初始治疗的年龄中位数为35(IQR:27~45)岁,以男性、本地、已婚或同居、异性性传播、基线CD4+T淋巴细胞计数(CD4)≤200个/μl、WHO分期Ⅰ期为主。第1、5、7、10年的累计生存率分别为96.75%、92.36%、91.87%、90.02%。多因素Cox比例风险回归模型分析显示,年龄越大死亡危险度越高,接受抗病毒治疗的〉60岁HIV/AIDS患者是≤20岁组的17.34倍(95% CI:2.11~142.71);基线WHO临床分期Ⅳ期患者死亡危险是Ⅰ期的2.83倍(95% CI:1.67~4.80);耐药患者死亡风险是不耐药患者死亡风险的3.26倍(95% CI:1.77~6.01);相较于同性性传播途径,血液传播是患者死亡的危险因素;CD4值越低,死亡风险越大;BMI〈18.5 kg/m2、未婚是患者死亡的独立危险因素。结论 宁波市HIV/AIDS患者抗病毒治疗效果显著,生存率较高。关爱老年人群,针对流行病学特征加强宣传教育,扩大监测范围,早发现早诊断早治疗,提高抗病毒治疗者的依从性是降低病死率的有效措施。 Objective To understand the epidemiology characteristics and survival status of HIV/AIDS patients with access to highly antiretroviral therapy (HAART) in Ningbo during 2004-2015. Methods A retrospective cohort study was conducted among HIV/AIDS patients diagnosed between 2004 and 2015. Life Tables were used to estimate survival rates, and Kaplan-Meier curve with Log rank test were used to describe the survival curves and the Cox proportional hazard model was used to determine predictors of mortality. Results Of the subjects, the median age when starting HAART was 35 years (IQR:27-45 years). Most of them were males, local residents, married, infected through heterosexual sexual transmission, and their baseline CD4 T cells counts were mainly ≤200 cells/μl, and most of them were at clinical stageⅠ(WHO). The cumulative survival rate was 96.75% for the first year, 92.36% for the fifth year, 91.87% for the seventh year and 90.02% for the tenth year. The risk of the mortality was 17.34 times higher for those aged 〉60 years compared with those aged ≤20 years (95%CI:2.11-142.71), 2.83 times higher for those at clinical stage Ⅳ(WHO) compared with those at clinical stageⅠ(WHO) (95%CI:1.67-4.80) and 3.26 times higher for those with drug resistance compared with those without drug resistance (95%CI:1.77-6.01). Blood transmission, lower CD4+ T cell level, BMI 〈18.5, unmarried were the risk factors for the mortality. Conclusions The effect of HAART was obvious in the HIV/AIDS patients in Ningbo, their survival rate was high. The finding indicated that it is necessary to strengthen the health care for old population and health education about AIDS prevention and control, and conduct large scale screening. Early discovery, early diagnosis, early treatment and improving treatment compliancy are still the effective ways to reduce the mortality.
出处 《中华流行病学杂志》 CAS CSCD 北大核心 2016年第9期1262-1267,共6页 Chinese Journal of Epidemiology
关键词 艾滋病 高效抗反转录病毒治疗 生存率 生存分析 危险因素 HIV/AIDS Highly antiretroviral therapy Survival probability Survival analysis Risk factor
  • 相关文献

参考文献25

  • 1豆智慧,赵燕,何云,何文生,计国平,徐臣,马烨,赵德才,于兰,张福杰.免费抗病毒治疗降低获得性免疫缺陷综合征患者病死率回顾性队列研究[J].中华预防医学杂志,2009,43(12):1091-1095. 被引量:46
  • 2Jiang HB, Xie NH, Cao BB, et ah Determinants of progression to AIDS and death following HIV diagnosis: a retrospective cohort study in Wuhan, China [J]. PLoS One, 2013, 8 (12) : e83078. DOI: 10.1371/j ournal.pone.0083078.
  • 3沈银忠,卢洪洲.艾滋病抗病毒治疗的新进展[J].上海医药,2014,35(21):9-13. 被引量:41
  • 4郑锦雷,徐云,何林,蒋均,杨介者.艾滋病抗病毒治疗生存分析研究进展[J].中华流行病学杂志,2015,36(12):1439-1444. 被引量:18
  • 5中华人民共和国卫生部,联合国艾滋病规划署,世界卫生组织.2011年中国艾滋病疫情估计[J].中国艾滋病性病,2012,18(1):14-16.
  • 6Zhang F J, Dou ZH, Ma Y, et al. Five-year outcomes of the China national free antiretroviral treatment program [J]. Ann Int Med, 2009, 151 (4) : 241-251. DOI: 10.7326/0003-4819-151-4- 200908180-00006.
  • 7Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study [J]. AIDS, 2006, 20 (8) : 1181- 1189. DOI : 10.1097/01 .aids.0000226959.87471.01.
  • 8Suligoi B, Zucchetto A, Grande E, et al. Risk factors for early mortality after AIDS in the cart era: a population-based cohort study in Italy[J]. BMC Infect Dis,2015, 15:229. DOI: 10.1186/ s 12879-015-0960-6.
  • 9Setegn T, Takele A, Gizaw T, et al. Predictors of mortality among adult antiretroviral therapy users in southeastern Ethiopia: retrospective cohort study [J]. AIDS Res Treat, 2015, 2015: 148769. DOI: 10.1155/2015/148769.
  • 10姚仕堂,段松,项丽芬,叶润华,杨跃诚,李艳玲,王继宝,杨锦,章银娣,杨海芹,时允,李如娟,翟志坚,丁雨生,杨卫华,丁盈盈,何纳.云南省德宏州3103例艾滋病患者抗病毒治疗后生存分析[J].中华流行病学杂志,2010,31(11):1215-1218. 被引量:72

二级参考文献103

  • 1梁飞立,何艳英,黄绍标,郑培衡,邓梅花,何燕,苏齐鉴.老年艾滋病抗病毒治疗六年生存情况及其影响因素分析[J].中华临床医师杂志(电子版),2012,6(20):165-166. 被引量:17
  • 2李敬云,李宏,李韩平,王哲,杨坤,辛天义,鲍作义,刘思扬.河南省部分地区HIV耐药性毒株流行状况及进化特征研究[J].军事医学科学院院刊,2005,29(1):8-12. 被引量:17
  • 3张福杰,曹韵贞,赵红心,等.国家免费艾滋病抗病毒药物治疗手册.2版.北京:人民卫生出版社,2008.
  • 4Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med, 1998,338:853-860.
  • 5Zhang F, Dou Z, Ma Y, et al. Five-Year Outcomes of the China national Free Antiretroviral Treatment Program. Ann Intern Med, 2009,151 : 242 -251.
  • 6Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr,2006,43:27-34.
  • 7Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med,2001,135 :17-26.
  • 8Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA, 2006,296 : 782 -793.
  • 9Zhang F, Dou Z, Yu L, et al. The Effect of Highly Active Antiretroviral Therapy on Mortality in HIV-Infected Former Plasma Donors in China. Clin Infect Dis ,2008,47:825-833.
  • 10中国疾病预防控制中心性病艾滋病预防控制中心.国家免费艾滋病抗病毒药物治疗手册[M].3版.北京:人民卫生出版社,2012.

共引文献288

同被引文献128

引证文献18

二级引证文献100

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部